Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. ALIM has been the subject of a number of other research reports. HC Wainwright lowered their price objective on shares of Alimera Sciences from $12.00 […]
Zacks Investment Research upgraded shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) from a strong sell rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports. According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization […]
SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- The global diabetic retinopathy market size is expected to reach USD 13.8 billion by 2030 registering a CAGR of 6.4%, according to a new report
According to Fact MR’s recent market research, sales of Ocular Drug Delivery Technology to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also p...
According to Fact MR’s recent market research, sales of Ocular Drug Delivery Technology to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also p...